# A Study of YTS109 Cell Injection in Subjects With Relapsed/Refractory Autoimmune Hemolytic Anemia

> **NCT06770504** · PHASE1 · NOT_YET_RECRUITING · sponsor: **Institute of Hematology & Blood Diseases Hospital, China** · enrollment: 7 (estimated)

## Conditions studied

- Autoimmune Hemolytic Anemia
- Anti-CD19 STAR T-cell Therapy
- Failure ≥3 Lines of Therapies

## Interventions

- **BIOLOGICAL:** YTS109

## Key facts

- **NCT ID:** NCT06770504
- **Lead sponsor:** Institute of Hematology & Blood Diseases Hospital, China
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-01-16
- **Primary completion:** 2025-12-30
- **Final completion:** 2026-12-30
- **Target enrollment:** 7 (ESTIMATED)
- **Last updated:** 2025-01-13

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06770504

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06770504, "A Study of YTS109 Cell Injection in Subjects With Relapsed/Refractory Autoimmune Hemolytic Anemia". Retrieved via AI Analytics 2026-07-13 from https://api.ai-analytics.org/clinical/NCT06770504. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*